Targeted Radionuclide Therapy
See how Bayer is investigating targeted radionuclide therapy across the oncology pipeline
Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.
Targeted Radionuclide Therapy
Targeted radionuclide therapy (TRT) is an evolving class of precision therapy for various tumors, whereby highly specific targeting moieties facilitate the delivery of a radioactive payload1,2
Bayer’s TRT portfolio includes novel targeting approaches combining alpha radionuclides with antibodies, small molecules, and peptide-based molecules. We are exploring targeted alpha therapy (TAT) for a range of solid tumors3-7
Alpha emitters deliver highly ionizing radiation to tumor cells and the tumor microenvironment, inducing DNA damage, cell cycle arrest, and cell death8-10
Properties of alpha particles include high linear energy transfer with short-range penetration, leading to anti-tumor activity while limiting exposure to surrounding normal tissue8,9
Compounds currently under development utilize actinium-225, an alpha particle–emitting radionuclide with a 10-day half-life10
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.